
Daphne Zohar (PureTech)
PureTech bags $200M from sale of Karuna shares — still sizzling from promising schizophrenia data
Cashing in on the exuberance around Karuna Therapeutics and its potential blockbuster CNS drug, PureTech has sold a chunk of the biotech’s shares to Goldman Sachs for $200 million.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters